Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celgene's New Regime: Hugin And Alles Discuss Handing Over The Reins

This article was originally published in Scrip

Executive Summary

Mark Alles has been in his first pharma chief executive role for six weeks, after stepping into former Celgene Corp. leader Bob Hugin's shoes in March. While Alles has been with the company for 12 years and in the pharma industry for three decades he brings new skills to the top spot at Celgene and a keen eye for keeping science at the fore of his corporate decision making.

You may also be interested in...



Inexperienced Biotech CEOs Impact Investor Confidence – Analyst Research

Median tenure of large cap US biotech CEOs has decreased from 11 years in 2007 to one year in 2017, Leerink analyst Geoffrey Porges determined in an analysis of seven biotechs over 15 years.

Snapshot: April Highlights

A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series. 

Transforming Patient Engagement At Novartis

Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC065004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel